Track topics on Twitter Track topics that are important to you
SOURCE: Johnson & Johnson
Four years ago, a disease that rarely made headlines — Ebola — raged in West Africa. There was no vaccine, treatment or cure. Though the initial response was slow, the international community ultimately mobilized resources, developed scientific innovations and promised to make sure a tragedy on the same scale would never happen again.
Today, Ebola is back, but the story is changing. The Democratic Republic of the Congo, where I started my career as a physician, is facing the second of two threatening Ebola outbreaks this year, but this time we're better prepared to respond thanks to new tools, including new vaccines. My company, Johnson & Johnson, is among those that accelerated the development of a vaccine and stands ready to deploy it when needed.
Ebola, and HIV before it, shows what can be accomplished once a disease is catapulted to the top of the global agenda. So it is puzzling to me why a far deadlier disease — tuberculosis — has never received this sort of attention and focus from the global community.
KEYWORDS: johnson & johnson, NYSE: JNJ, tuberculosis
Marburg and Ebola Virus Infections
Ebola virus and Marburg virus are related viruses that cause hemorrhagic fevers — illnesses marked by severe bleeding (hemorrhage), organ failure and, in many cases, death. Both viruses are native to Africa, where sporadic outbreaks have occurred f...
Human Immuno Deficiency Virus (HIV)
Human Immunodeficiency Virus (HIV), the causative agent of AIDS. The Human Immunodeficiency Virus, more commonly known as HIV, is a member of the lentivirus sub-set of the retrovirus family of pathogens. It causes AIDS, or Acquired Immuno Deficiency Sy...